Monday, 26 Jun 2017

You are here

Adalimumab Effective in Pediatric Plaque Psoriasis

Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis.  The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.

This multicenter, multinational study enrolled 114 children ages 4 to 18 yrs with severe plaque psoriasis and randomized them to treatment with adalimumab (ADA) (0·8 mg/kg or 0·4 mg/kg subcutaneously)every other week after week 1, or oral methotrexate (MTX) once weekly (0·1–0·4 mg/kg) for 16 weeks.

A week 16  PASI75 was achieved moreso with ADA (58%) compared to MTX (32%).

Clearing or minimal psoriasis was seen with 61% of ADA and 41% of the MTX patients.

There were no unexpected toxicities or infections and 3 serious adverse events were reported, all in patients in the adalimumab 0·4 mg/kg group, and were not judged to be related to study drug.

ADA appears to be effective and safe in children with plaque psoriasis. 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

IV Golimumab in Psoriatic Arthritis

Based on recent clinical trials, the makers of golimumab have petitioned the FDA for new indications in PsA and AS. Trials for PsA (GO-VIBRANT) and AS (GO-ALIVE) were presented at last weeks EULAR 2017 meeting in Madrid, Spain.

Tildrakizumab, an IL-23 Inhibitor, is Successful in Plaque Psoriasis

Therapeutic options for cutaneous psoriasis (and psoriatic arthritis as well) are rapidly expanding.  Lancet has published the impressive results of two phase III trials of tildrakizumab, a IgG1 antibody against interleukin 23 p19, in patients with active chronic plaque psoriasis.

Low Dose Treatment in Ankylosing Spondylitis Still Effective

About one-third of ankylosing spondylitis patients who cut their etanercept (Enbrel) dose in half maintained responses over 4 years, compared with two-thirds who stayed on standard therapy, researchers reported.

Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial

Ixekizumab (Taltz) is currently approved for use in plaque psoriasis and is being developed for use in psoriatic arthritis (PsA). New results show IXE to be highly effective at skin and joint outcomes in PsA patients who have failed a TNF inhibitor (TNFi).

Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis

Claims data analysis of 4245 psoriatic arthritis patients on TNF inhibitors showed both higher than expected durations of noncompliance and higher than label dosing - all at an increased cost.